Amp Volatility Score
Catalyst Info & Data Links
TITLE: Belapectin (GR-MD-02) for Plaque Psoriasis
- Phase 2
WHAT IS THE NEXT CATALYST EVENT?
Information on Next Steps
WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?
MECHANISM OF ACTION
Belapectin (GR-MD-02) is a complex carbohydrate drug that targets galectin-3, a critical protein in the pathogenesis of NASH and fibrosis. Galectin-3 plays a major role in diseases that involve scarring of organs including fibrotic disorders of the liver, lung, kidney, heart and vascular system. Belapectin binds to galectin-3 and disrupts its function.
Updated by JM
GALT, Galectin Therapeutics, Belapectin (GR-MD-02), NASH-cirrhosis, Plaque Psoriasis, Atopic Dermatitis (Eczema)
Prior Data (click to view full image)
Trial Design / Revenue (click to view full image)
See What The Community Is Saying - Click To See Full Post